Skip to content
Screener

Arcus Biosciences RCUS Business Segments — Total revenues

Similar metrics at other companies

Intuitive Machines, Inc. logo
LUNRReportable Segment — Total revenues
$186.73M+199%
LanzaTech Global, Inc. logo
LNZAReportable Segment — Total revenues
$12.02M+26.8%
BGC Group, Inc. logo
BGCReportable Segment — Total revenues
$955.48M+43.8%
Alignment Healthcare logo
ALHCReportable Segment — Total revenues
$1.24B+33.3%
Trinet Group logo
TNETReportable Segment — Total revenues
$1.23B-5.1%
Arcutis Biotherapeutics, Inc. logo
ARQTReportable Segment — Total revenues
$129.86M+59.3%

Other financials

Income statement

See full
Revenue$41.0M-74.4%
Operating income-$96.0M-1,100%
Net income-$91.0M
EPS (diluted)-$0.72

Balance sheet

See full
Cash & equivalents$150.0M-39.5%
Total debt$114.0M+4.6%
Total equity$464.0M-15.5%
Total assets$924.0M-14.0%

Cash flow

See full
Operating cash flow-$119.0M+10.5%
CapEx-
Free cash flow-$119.0M+10.5%

Valuation

See full
Market cap$3.61B+259%
Enterprise value$3.57B+312%
P/S30.8×+27.0×

Profitability

See full
Operating margin-415.4%-756pp
Net margin-393.2%-663pp
FCF margin-406%

Returns & leverage

See full
Return on equity-90.8%+373pp
Debt / equity0.2×0.0×
Current ratio3.8×-0.7×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001724521-26-000044
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total revenues4116058188
Adjusted for expense (income):
Late-stage development programs (1)5174111129
Early-stage development and preclinical programs (2)21383980
Compensation and personnel costs5861129128
Depreciation and amortization2255
Interest income, net(5)(8)(11)(18)
Other segment items (3)22264047

Item 1. Financial Statements

FAQ

What is Arcus Biosciences's business segments — total revenues?
Arcus Biosciences (RCUS) reported business segments — total revenues of $41M in Q2 2026.
How has Arcus Biosciences's business segments — total revenues changed year-over-year?
Arcus Biosciences's business segments — total revenues decreased by 74.4% year-over-year, from $160M to $41M.
What is the long-term trend for Arcus Biosciences's business segments — total revenues?
Over 3 years (2022 to 2025), Arcus Biosciences's business segments — total revenues has grown at a 30.2% compound annual growth rate (CAGR), from $112M to $247M.
What does business segments — total revenues mean?
Represents the total gross income generated by the primary business segment through its core operations, including product sales, licensing fees, and collaboration revenue. This metric serves as a key indicator of the segment's market traction and commercial success in its therapeutic focus areas.

Ask your AI about Arcus Biosciences's business segments — total revenues.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude